You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. The Allogeneic Heart Stem Cell Trial in Hypoplastic Left Heart Syndrome Patients

    SBC: CAPRICOR, INC.            Topic: NHLBI

    DESCRIPTION provided by applicant One of the most complex forms of congenital heart disease hypoplastic left heart syndrome HLHS affects an average of in every newborns with a mortality rate of up to percent during the first year of life The overall goal f our research is to develop safe and effective ways to improve short term and long term survival rates in babies born with HL ...

    STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
  2. CODA Assembly of Mutant Genes

    SBC: VERDEZYNE, INC.            Topic: N/A

    DESCRIPTION (provided by applicant): The general goal of this proposal is to assemble directed mutant gene sets quickly, cheaply, easily, and reliably. Mutant gene sets can share sub-assemblies, yielding savings of time, cost, and effort not possible if designed and assembled all as single genes. The approach is to build upon experience gained in Phase I, to extend and generalize methods of DNA de ...

    STTR Phase II 2009 Department of Health and Human ServicesNational Institutes of Health
  3. A Novel Therapeutic that Harnesses Microtubules to Promote Cavernous Nerve Regeneration after Radical Prostatectomy

    SBC: MICROCURES INC            Topic: 300

    Radical prostatectomy (RP) is a commonly used treatment option for localized prostate cancer, which carries a high risk for development of erectile dysfunction (ED) because of cavernous nerve (CN) injury. Even newer, nerve-sparing, robotic procedures do not convincingly improve erectile function (EF) outcomes after RP. In addition, ED resulting from RP is often refractory to treatment by orally ad ...

    STTR Phase II 2021 Department of Health and Human ServicesNational Institutes of Health
  4. The nGoggle: A portable brain-based device for assessment of visual function deficits

    SBC: NGOGGLE INC            Topic: N

    PROJECT SUMMARY Assessment of loss of visual function outside the foveal area is an essential component of the management of numerous conditionsincluding glaucomaretinal and neurological disordersDespite the significant progress achieved with the development of standard automated perimetrySAPmany decades agoassessment of visual field loss with SAP still has significant drawbacksSAP testing is limi ...

    STTR Phase II 2018 Department of Health and Human ServicesNational Institutes of Health
  5. Therapeutic peanut allergen Fc gamma chimeric proteins to treat peanut allergy

    SBC: TUNITAS THERAPEUTICS, INC.            Topic: NIAID

    DESCRIPTION (provided by applicant): The overall goal of this Phase 2 STTR is to develop and commercialize a novel approach for allergen specific immunotherapy as a treatment for severe food allergy. Currently treatment to prevent severe food reactions isa major unmet need. There is no effective therapy, the only treatment being strict avoidance and emergency measures should an exposure occur. Th ...

    STTR Phase II 2012 Department of Health and Human ServicesNational Institutes of Health
  6. A GIP Companion Drug for Enhancing Metabolic Benefits of Long-Acting GLP-1

    SBC: VELUM INC            Topic: NIA

    Project Summary There is a world-wide “twin epidemic” of obesity and Type 2 Diabetes (T2D), with an urgent need to find effective new drug treatments for inducing weight loss. Stable derivatives of the endogenous glucoregulatory hormone, glucagon-like peptide-1 (GLP1) are in clinical use for the treatment of T2D but are also of great interest as an emerging treatment of obesity. Another closel ...

    STTR Phase II 2021 Department of Health and Human ServicesNational Institutes of Health
  7. Dual Headed CZT Breast Imager

    SBC: GAMMA MEDICA-IDEAS, INC.            Topic: N/A

    DESCRIPTION (provided by applicant): The focus of this proposal is the development of a novel in-vivo imaging device (Molecular Breast Imaging system) that incorporates a clinical validation experiment and a limited pilot and a clinical feasibility evaluation for pre-clinical and clinical studies. Our primary intent is to facilitate the proof of feasibility of this novel imaging device for early ...

    STTR Phase II 2008 Department of Health and Human ServicesNational Institutes of Health
  8. Real Time Oxygen Monitoring for Tissue Health Peripheral Artery Disease Application

    SBC: PROFUSA, INC.            Topic: NHLBI

    DESCRIPTION provided by applicant Continuous biochemical monitoring has the power to change currently accepted standards of care shifting the emphasis from treating illness to maintaining health Point in time snapshots of a patientandapos s health can miss critical fluctuations or early warning signs that might warrant early interventions or changes in disease treatment and management PROFUS ...

    STTR Phase II 2016 Department of Health and Human ServicesNational Institutes of Health
  9. Development of PAR2 Inhibitors for the Treatment of Nonalcoholic steatohepatitis

    SBC: OASIS PHARMACEUTICALS, LLC            Topic: NIDDK

    DESCRIPTION provided by applicant Non alcoholic steatohepatitis NASH is characterized by fatty changes in the liver with inflammation and hepatocellular injury that in advanced stages leads to fibrosis and cirrhosis and high mortality rates NASH is frequently associated with other common metabolic abnormalities such as insulin resistance and visceral obesity Liver transplantation is curren ...

    STTR Phase II 2014 Department of Health and Human ServicesNational Institutes of Health
  10. Prospective/Retrospective Motion Correction System for Motion Robust Pediatric MR

    SBC: ROBIN MEDICAL INC            Topic: NIMH

    DESCRIPTION (provided by applicant): The long term objective of the project is to develop a new motion robust magnetic resonance imaging (MRI) technology. Magnetic resonance imaging is a powerful tool that aids in the diagnosis of individual subjects, guides their clinical care, ad provides insights into the mechanisms of normal and atypical development. The characterization of mental health disor ...

    STTR Phase II 2012 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government